Optimer's Deficid Gets Expected FDA Nod in C. Diff. Indication
By Jennifer Boggs
Tuesday, May 31, 2011
Executives of Optimer Pharmaceuticals Inc. didn't have to wait until after the long weekend for an FDA decision on the company's macrolide antibiotic Dificid (fidaxomicin). Though the PDUFA date was set for May 30, the agency approved the drug Friday afternoon for treating Clostridium difficile-associated diarrhea (CDAD), a common hospital-acquired infection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.